Reid M. Huber - 03 Jan 2023 Form 4/A - Amendment Insider Report for BELLICUM PHARMACEUTICALS, INC

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 03 Jan 2023
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 20 Jan 2023, 13:24:51 UTC
Original report date: 05 Jan 2023
Prior SEC filing: 02 Sep 2022
Next SEC filing: 08 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Richard A. Fair, Attorney-in-Fact

Key filing fact

Reid M. Huber filed Form 4/A - Amendment for BELLICUM PHARMACEUTICALS, INC on 20 Jan 2023.

Key facts

This page summarizes Reid M. Huber's Form 4/A - Amendment filing for BELLICUM PHARMACEUTICALS, INC.
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 20 Jan 2023, 13:24.

Change

Previous filing in this sequence was filed on 02 Sep 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BLCM transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +80,968
Change %: +123%
Price: $0.000000
Shares after: 146,951
Date: 03 Jan 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This amendment is being filed to correct the mathematical error in the amount of securities acquired and the amount of securities beneficially owned following reported transaction on the original Form 4 filed with the SEC on January 5, 2023.